Bruker Corporation $BRKR Shares Purchased by Ieq Capital LLC

Key Points

• Ieq Capital LLC increased its stake in Bruker Corporation by 16.8% during Q1, owning 68,858 shares valued at $2.87 million.
• Bruker reported $0.32 earnings per share, missing estimates and showing a 4% year-over-year revenue decrease for the quarter.
• The company has announced a quarterly dividend of $0.05 per share, with a corresponding dividend yield of 0.6%.

Ieq Capital LLC lifted its holdings in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 16.8% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 68,858 shares of the medical research company's stock after purchasing an additional 9,908 shares during the quarter. Ieq Capital LLC's holdings in Bruker were worth $2,874,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in BRKR. Pinnacle Bancorp Inc. acquired a new stake in shares of Bruker during the first quarter worth about $29,000. Allworth Financial LP raised its stake in shares of Bruker by 92.4% in the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after acquiring an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of Bruker by 1,354.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock valued at $33,000 after acquiring an additional 745 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Bruker in the first quarter valued at $42,000. Finally, MassMutual Private Wealth & Trust FSB raised its stake in shares of Bruker by 274.9% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after acquiring an additional 800 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on BRKR shares. Wells Fargo & Company reduced their price objective on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 5th. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the company a "buy" rating in a report on Monday, August 4th. Stifel Nicolaus set a $40.00 target price on shares of Bruker and gave the company a "hold" rating in a report on Tuesday, August 5th. Bank of America reduced their target price on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Finally, Citigroup cut their price target on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $51.30.

Insider Activity at Bruker

In other Bruker news, CEO Frank H. Laukien bought 2,608 shares of the business's stock in a transaction dated Friday, June 6th. The shares were acquired at an average cost of $38.36 per share, with a total value of $100,042.88. Following the acquisition, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. The trade was a 0.01% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 27.30% of the stock is owned by insiders.

Bruker Stock Performance

Shares of BRKR traded up $0.27 during midday trading on Thursday, reaching $29.62. 12,112,262 shares of the stock were exchanged, compared to its average volume of 2,589,954. The business's 50-day moving average price is $37.59 and its 200 day moving average price is $39.96. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $72.94. The company has a market capitalization of $4.49 billion, a price-to-earnings ratio of 56.93, a PEG ratio of 2.79 and a beta of 1.21.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The firm had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. During the same quarter last year, the firm posted $0.52 EPS. The firm's revenue for the quarter was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, sell-side analysts expect that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker's payout ratio is presently 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.